Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
Abstract Introduction There is a need for biomarkers to predict response and survival to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC). Soluble PD-L1 (sPD-L1) has shown biomarker potential. The objective of this study was to evaluate sPD-L1 in patie...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer
2025-08-01
|
| Serija: | Cancer Immunology, Immunotherapy |
| Teme: | |
| Online pristup: | https://doi.org/10.1007/s00262-025-04126-9 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|